Patients are categorized as CD49d‐low (< 30% CD49d‐positive CLL cells, Fig. 3C) or CD49d‐high (≥ 30%, Fig. 3D) based on flow cytometry analysis of peripheral blood CLL cells [120, 121, 122]. This evidence concerns the gene ITGA4 and B-cell chronic lymphocytic leukemia.